From Diagnosis to Treatment. Clinical Applications of Nanotechnology in Thoracic Surgery.

Thoracic Surgery Clinics

Volumn 26, Issue 2, 2016, Pages 215-228

  Digesu, Christopher S ^a   Hofferberth, Sophie C ^a   Grinstaff, Mark W ^b,c,d   Colson, Yolonda L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Boston University   (United States)

^c Boston University   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lung cancer; Nanotechnology; Nanotheranostics; Thoracic surgery

Indexed keywords

CARBON NANOTUBE; DENDRIMER; LIPOSOME; NANOCRYSTAL; NANOPARTICLE; POLYMERIC NANOPARTICLE; QUANTUM DOT; UNCLASSIFIED DRUG;

CONCENTRATION (PARAMETERS); DRUG DELIVERY SYSTEM; DRUG RELEASE; GENE TARGETING; HUMAN; INTRAOPERATIVE PERIOD; MICELLE; NANOANALYSIS; NANOIMAGING; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERANOSTIC NANOMEDICINE; THORAX SURGERY; LUNG NEOPLASMS; PROCEDURES;

HUMANS; LUNG NEOPLASMS; NANOTECHNOLOGY; THORACIC SURGERY; THORACIC SURGICAL PROCEDURES;

EID: 84963939236     PISSN: None     EISSN: 15585069     Source Type: Journal    
DOI: 10.1016/j.thorsurg.2015.12.009     Document Type: Review

References (88)

1. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3(1):16-20.
2. Heath J.R., Davis M.E. Nanotechnology and cancer. Annu Rev Med 2008, 59:2251-2265.
3. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5(3):161-171.
4. Zhu L., Torchilin V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr Biol (Camb) 2013, 5(1):96-107.
5. Howlader N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2012. Bethesda (MD): National Cancer Institute. Available at: . Accessed August 10, 2015. http://seer.cancer.gov/csr/1975_2012/.
6. Yanagawa J., Rusch V.W. Current surgical therapy for stage IIIA (N2) non-small cell lung cancer. Semin Thorac Cardiovasc Surg 2011, 23(4):291-296.
7. Ma P., Mumper R.J. Paclitaxel nano-delivery systems: a comprehensive review. J Nanomed Nanotechnol 2013, 4(2):1000164.
8. Badea C.T., Athreya K.K., Espinosa G., et al. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLoS One 2012, 7(4):e34496.
9. Hill T.K., Abdulahad A., Kelkar S.S., et al. Indocyanine green-loaded nanoparticles for image-guided tumor surgery. Bioconjug Chem 2015, 26(2):294-303.
10. Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8(24):1112-1120.
11. Zhang G., Zeng X., Li P. Nanomaterials in cancer-therapy drug delivery system. J Biomed Nanotechnol 2013, 9(5):741-750.
12. Biswas S., Deshpande P.P., Perche F., et al. Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett 2013, 335(1):191-200.
13. Bazak R., Houri M., El Achy S., et al. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol 2015, 141(5):769-784.
14. Gao L., Liu G., Ma J., et al. Drug nanocrystals: in vivo performances. J Control Release 2012, 160(3):418-430.
15. Pawar V.K., Singh Y., Meher J.G., et al. Engineered nanocrystal technology: in-vivo fate, targeting and applications in drug delivery. J Control Release 2014, 183:51-66.
16. Junghanns J.U., Müller R.H. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008, 3(3):295-309.
17. Joshi M., Liu X., Belani C.P. Taxanes, past, present, and future impact on non-small cell lung cancer. Anticancer Drugs 2014, 25(5):571-583.
18. Liu F., Park J.Y., Zhang Y., et al. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci 2010, 99(8):3542-3551.
19. Azzazy H.M., Mansour M.M., Kazmierczak S.C. From diagnostics to therapy: prospects of quantum dots. Clin Biochem 2007, 40(13-14):917-927.
20. Schulz M.D., Khullar O., Frangioni J.V., et al. Nanotechnology in thoracic surgery. Ann Thorac Surg 2010, 89(6):S2188-S2190.
21. Akerman M.E., Chan W.C., Laakkonen P., et al. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 2002, 99(20):12617-12621.
22. Bottrill M., Green M. Some aspects of quantum dot toxicity. Chem Commun (Camb) 2011, 47(25):7039-7050.
23. Lin G., Ouyang Q., Hu R., et al. In vivo toxicity assessment of non-cadmium quantum dots in BALB/c mice. Nanomedicine 2015, 11(2):341-350.
24. Muthu M.S., Leong D.T., Mei L., et al. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4(6):660-677.
25. Kraft J.C., Freeling J.P., Wang Z., et al. Emerging Research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014, 103(1):29-52.
26. Wang X., Zhou J., Wang Y., et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 2010, 46(8):1474-1480.
27. Guo Y., Wang L., Lv P., et al. Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett 2015, 9(3):1065-1072.
28. Steichen S.D., Caldorera-Moore M., Peppas N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013, 48(3):416-427.
29. Majoros I.J., Myc A., Thomas T., et al. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 2006, 7(2):572-579.
30. Walter A., Billotey C., Garofalo A., et al. Mastering the shape and composition of dendronized iron oxide nanoparticles to tailor magnetic resonance imaging and hyperthermia. Chem Mater 2014, 26(18):5252-5264.
31. Wang H., Zheng L., Peng C., et al. Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adenocarcinoma. Biomaterials 2013, 34(2):470-480.
32. Fischer D., Li Y., Ahlemeyer B., et al. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003, 24(7):1121-1131.
33. Madaan K., Kumar S., Poonia N., et al. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 2014, 6(3):139-150.
34. Jones C.F., Campbell R.A., Franks Z., et al. Cationic PAMAM dendrimers disrupt key platelet functions. Mol Pharmacol 2012, 9(6):1599-1611.
35. Rastogi V., Yadav P., Bhattacharya S.S., et al. Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J Drug Deliv 2014, 2014:670815.
36. Rodriguez-Yanez Y., Munoz B., Albores A. Mechanisms of toxicity by carbon nanotubes. Toxicol Mech Methods 2013, 23(3):178-195.
37. Takagi A., Hirose A., Nishimura T., et al. Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008, 33(1):105-116.
38. Kanno J., Takagi A., Hirose A., et al. Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008, 33(1):105-116.
39. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
40. Colson Y.L., Grinstaff M.W. Biologically responsive polymeric nanoparticles for drug delivery. Adv Mater 2012, 24(28):3878-3886.
41. Liu C.W., Lin W.J. Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin. Int J Nanomedicine 2012, 7:4749-4767.
42. Vasey P.A., Kaye S.B., Morrison R., et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999, 5(1):83-94.
43. Langer C.J. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer 2004, 6(Suppl 2):S85-S88.
44. Langer C.J., O'byrne K.J., Socinski M.A. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 2008, 3(6):623-630.
45. Frank D., Tyagi C., Tomar L., et al. Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors. Int J Nanomedicine 2014, 9:589-613.
46. Kim D.W., Kim S.Y., Kim H.K., et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007, 18(12):2009-2014.
47. Moghimi S.M., Hunter A.C., Murray J.C., et al. Cellular distribution of nonionic micelles. Science 2004, 303(5658):626-628.
48. Hsieh W.J., Liang C.J., Chieh J.J., et al. In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int J Nanomedicine 2012, 7:2833-2842.
49. Mallia R.J., McVeigh P.Z., Fisher C.J. Wide-field multiplexed imaging of EGFR- targeted cancers using topical application of NIR SERS nanoprobes. Nanomedicine (Lond) 2015, 10(1):89-101.
50. Koyama T., Shimura M., Minemoto Y., et al. Evaluation of selective tumor detection by clinical magnetic resonance imaging using antibody-conjugated superparamagnetic iron oxide. J Control Release 2012, 159(3):413-418.
51. Key J., Leary J.F. Nanoparticles for multimodal in vivo imaging in nanomedicine. Int J Nanomedicine 2014, 9:711-726.
52. Kong W.H., Lee W.J., Cui Z.Y., et al. Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials 2007, 28(36):5555-5561.
53. Fischer B., Lassen U., Mortensen J., et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361(1):32-39.
54. Chen V.W., Ruiz B.A., Hsieh M.C., et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer 2014, 120(Suppl 23):3781-3792.
55. Zheng J., Muhanna N., De Souza R., et al. A multimodal nano agent for image-guided cancer surgery. Biomaterials 2015, 67:160-168.
56. Anayama T., Nakajima T., Dunne M., et al. A novel minimally invasive technique to create a rabbit VX2 lung tumor model for nano-sized image contrast and interventional studies. PLoS One 2013, 8(6):e67355.
57. D'Cunha J., Herndon J.E., Herzan D.L., et al. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer 2005, 48(2):241-246.
58. Liptay M.J., D'amico T.A., Nwogu C., et al. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol 2009, 4(2):198-202.
59. Rzyman W., Hagen O.M., Dziadziuszko R., et al. Blue-dye intraoperative sentinel lymph node mapping in early non-small lung cancer. Eur J Surg Oncol 2006, 32(4):462-465.
60. Gilmore D.M., Khullar O.V., Jaklitsch M.T., et al. Identification of metastatic nodal disease in a phase 1 dose-escalation trial of intraoperative sentinel lymph node mapping in non-small cell lung cancer using near-infrared imaging. J Thorac Cardiovasc Surg 2013, 146(3):562-570.
61. Soltesz E.G., Kim S., Laurence R.G., et al. Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg 2005, 79(1):269-277.
62. Parungo C.P., Colson Y.L., Kim S.W., et al. Sentinel lymph node mapping of the pleural space. Chest 2005, 127(5):1799-1804.
63. Parungo C.P., Ohnishi S., Kim S.W., et al. Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J Thorac Cardiovasc Surg 2005, 129(4):844-850.
64. Young R.C., Ozols R.F., Myers C.E. The anthracycline antineoplastic drugs. N Engl J Med 1981, 305(3):139-153.
65. Hollis C.P., Weiss H.L., Evers B.M., et al. In vivo investigation of hybrid paclitaxel nanocrystals with dual fluorescent probes for cancer theranostics. Pharm Res 2014, 31(6):1450-1459.
66. Zhao T., Chen H., Dong Y., et al. Paclitaxel-loaded poly(glycolide-co- ɛ-caprolactone )-b-D-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy. Int J Nanomedicine 2013, 8:1947-1957.
67. Zhang C., Qu G., Sun Y., et al. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel. Biomaterials 2008, 29(9):1233-1241.
68. Cheng R., Meng F., Deng C., et al. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 2013, 34(14):3647-3657.
69. Stolzoff M., Ekladious I., Colby A.H., et al. Synthesis and characterization of hybrid polymer/lipid expansile nanoparticles: imparting surface functionality for targeting and stability. Biomacromolecules 2015, 16(7):1958-1966.
70. Liu R., Gilmore D.M., Zubris K.A., et al. Prevention of nodal metastases in breast cancer following the lymphatic migration of paclitaxel-loaded expansile nanoparticles. Biomaterials 2013, 34(7):1810-1819.
71. Cheng R., Feng F., Meng F., et al. Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. J Control Release 2011, 152(1):2-12.
72. Nguyen C.T., Tran T.H., Amiji M., et al. Redox-sensitive nanoparticles from amphiphilic cholesterol-based block copolymers for enhanced tumor intracellular release of doxorubicin. Nanomedicine 2015, 11(8):2071-2082.
73. Voon S.H., Kiew L.V., Lee H.B., et al. In vivo studies of nanostructure-based photosensitizers for photodynamic cancer therapy. Small 2014, 24:4993-5013.
74. Jiang F., Lilge L., Grenier J., et al. Photodynamic therapy of U87 human glioma in nude rat using liposome-delivered photoforin. Lasers Surg Med 1998, 22(2):74-80.
75. Jian W.H., Yu T.W., Chen C.J., et al. Indocyanine green-encapsulated hybrid polymeric nanomicelles for photothermal cancer therapy. Langmuir 2015, 31(22):6202-6210.
76. Yang S., Li N., Liu Z., et al. Amphiphilic copolymer coated upconversion nanoparticles for near-infrared light triggered dual anticancer treatment. Nanoscale 2014, 6(24):14903-14910.
77. Chen J., Wang L., Yao Q., et al. Drug concentrations in axillary lymph nodes after lymphatic chemotherapy on patients with breast cancer. Breast Cancer Res 2004, 6(4):R474-R477.
78. Qian Y., Qiu M., Wu Q., et al. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Sci Rep 2014, 4:7490.
79. Kuroda S., Tam J., Roth J.A., et al. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine 2014, 9:3825-3839.
80. Draz M.S., Fang B.A., Zhang P., et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 2014, 4(9):872-892.
81. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8(2):129-138.
82. Merkel O.M., Rubinstein I., Kissel T. siRNA delivery to the lung: what's new?. Adv Drug Deliv Rev 2014, 75:112-128.
83. Chen Y., Gu H., Zhang D.S., et al. Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier. Biomaterials 2014, 35(38):10058-10069.
84. Guo C., Al-Jamal W.T., Toma F.M., et al. Design of cationic multiwalled carbon nanotubes as efficient siRNA vectors for lung cancer xenograft eradication. Bioconjug Chem 2015, 26(7):1370-1379.
85. Luk B.T., Zhang L. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Inter 2014, 6(24):21859-21873.
86. Wang C., Ravi S., Garapati U.S., et al. Multifunctional chitosan magnetic-graphene (CMG) nanoparticles: a theranostic platform for tumor-targeted co- delivery of drugs, genes and MRI contrast agents. J Mater Chem B Mater Biol Med 2013, 1(35):4396-4405.
87. Khullar O.V., Griset A.P., Gibbs-Strauss S.L., et al. Nanoparticle migration and delivery of Paclitaxel to regional lymph nodes in a large animal model. J Am Coll Surg 2012, 214(3):328-337.
88. Khullar O., Frangioni J.V., Grinstaff M., et al. Image-guided sentinel lymph node mapping and nanotechnology-based nodal treatment in lung cancer using invisible near-infrared fluorescent light. Semin Thorac Cardiovasc Surg 2009, 21(4):309-315.